Replies to post #819358 on NorthWest Biotherapeutics Inc (NWBO)

[manibiotech]

Not sure it was such a good move to pay for such a pessimistic report in my opinion . More or less implying that even on approval SP won’t be anywhere close to uplisting levels. So stay comfortable with OTC .

[bas2020]

Who paid whom? It reads to me that First Berlin paid NWBO for access to information they needed to put this "analysis" together. Ultimately, the cabal paid it when they paid First Berlin to publish it.

The author, First Berlin, or a company associated with First Berlin reached an agreement with the Northwest Biotherapeutics Inc. for preparation of a financial analysis for which remuneration is owed.

Don't you know that these cabal shysters put out dishonest hit pieces all the time? Some blatant and some very subtle.

[attilathehunt]

for which remuneration is owed.

Owed…Not Paid!!!….Most likely the amount owed is based on the increased share price average for the next 60 days. The higher the share price the higher the amount owed….Expect dilution to take off after the next report…

Where is the MHRA decision???? Give us the decision or give us an update on the reason(s) for the delay!

824 days….

[flipper44]

I’m starting to suspect an upcoming delayed 10K.

Reasons.

1. Chancery Laster 🐌 still hasn’t signed an order from the settlement hearing on March 16.

2. MHRA Guidance editors 🐌 still haven’t published ECA (final version) Guideline.

[branster]

Baxers, did you see the last hightlighted line. QUALIFIED INSTITUTIONAL INVESTORS
First Berlin financial analyses are intended exclusively for qualified institutional investors.
This report is not intended for distribution in the USA and/or Canada. Not sure the intention of that statement....

Lastly, why not pay for a United States Analyst, why go overseas ??

[HyGro]

Sorry, there has been no deal between a BP and any OTC biotech drug company in the last decade. Look at Merck, that has full exposure to all things DCVax-L and has made numerous oncology biotech companies in the last two years passing over DCVax-L repeatedly. A BP could buy NWBO for pocket change but no takers.

[HyGro]

Sorry, there has been no deal between a BP and any OTC biotech drug company in the last decade. Look at Merck, that has full exposure to all things DCVax-L and has made numerous oncology biotech companies in the last two years passing over DCVax-L repeatedly. A BP could buy NWBO for pocket change but no takers.

[manibiotech]

And they also didn’t take into account “The Vault”. This firm’s research analysts likely don’t have level 4 access. 😊